Provided by Tiger Fintech (Singapore) Pte. Ltd.

Clearside Biomedical

0.8330
-0.0087-1.03%
Post-market: 0.85000.0170+2.04%16:06 EDT
Volume:43.49K
Turnover:36.32K
Market Cap:64.26M
PE:-1.79
High:0.8698
Open:0.8410
Low:0.8249
Close:0.8417
Loading ...

Company Profile

Company Name:
Clearside Biomedical
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
32
Office Location:
900 North Point Parkway,Suite 200,Alpharetta,Georgia,United States
Zip Code:
30005
Fax:
678 270 4033
Introduction:
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Directors

Name
Position
Daniel H. White
Director,President and Chief Executive Officer
William D. Humphries
Director and Chairman
Christy L. Shaffer
Director
Clay B. Thorp
Director
Evgeny Zaytsev
Director
George Lasezkay
Director
Gerald D. Cagle
Director
Richard Croarkin
Director

Shareholders

Name
Position
Daniel H. White
Director,President and Chief Executive Officer
Charles A. Deignan
Chief Financial Officer
Brion Raymond
Chief Commercial Officer
Glenn Noronha
Chief Scientific Officer